Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma

Inclusion Criteria: * Hospital in- or out patients * Either sex * 18 to 75 years of age * With hepatocellular carcinoma treated successfully with surgical resection or percutaneous ablative treatment within 4 and 8 weeks, respectively, prior to inclusion. * All patients must give their signed informed consent to join the study. Exclusion Criteria: * Patients previously treated with any anti-cancer therapy for HCC except for surgical resection and percutaneous ablative therapy * Patients treated with chemotherapy or other anti-cancer therapy (except surgical resection or percutaneous ablative treatment) in the previous 4 weeks * Patients with another primary tumor except basocellular carcinoma of the skin or in situ carcinoma of the cervix within the last 2 years * With a history of renal stone(s) * With a life expectancy \< 3 months * WHO performance status 3 or 4. * Patients with hypercalcemia (ionised serum calcium \> 1.35 mmol/l or albumin corrected serum calcium \> 2.68 mmol/l), previous/current calcium metabolic disease, taking calcium-lowering therapy or medication known to affect systemic calcium metabolism, or with marked laboratory abnormalities. * Patients with recurrent hepatocellular carcinoma, with known extrahepatic metastases, Okuda stage III disease and patients with a Child-Pugh score of C are also excluded.